Literature DB >> 15161055

The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities.

Yu-Jun Cai1, Qing-Yi Wei, Jian-Guo Fang, Li Yang, Zhong-Li Liu, James H Wyche, Zhiyong Han.   

Abstract

We compared the abilities of trans-resveratrol and seven analogs to inhibit an azo compound-induced peroxidation of linoleic acid in vitro and to induce apoptosis in cultured human leukemia cells. The results showed that both the antioxidant and apoptotic activities of the analogs containing 3,4-dihydroxyl groups were significantly higher than those of the trans-resveratrol and the other analogs. Hence, the 3,4-dihydroxyl groups were important for trans-resveratrol analogs to exhibit concurrent high antioxidant and apoptotic activities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161055

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.

Authors:  Katarzyna Kupisiewicz; Patrice Boissy; Basem M Abdallah; Frederik Dagnaes Hansen; Reinhold G Erben; Jean-Francois Savouret; Kent Søe; Thomas L Andersen; Torben Plesner; Jean-Marie Delaisse
Journal:  Calcif Tissue Int       Date:  2010-09-15       Impact factor: 4.333

2.  4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cells.

Authors:  Amruta Ronghe; Anwesha Chatterjee; Bhupendra Singh; Prasad Dandawate; Fatma Abdalla; Nimee K Bhat; Subhash Padhye; Hari K Bhat
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-09       Impact factor: 4.219

3.  Resveratrol (3,5,4'-trihydroxystilbene) and its properties in oral diseases.

Authors:  Donatella Perrone; Maria Pia Fuggetta; Fatima Ardito; Andrea Cottarelli; Anna De Filippis; Giampietro Ravagnan; Salvatore De Maria; Lorenzo Lo Muzio
Journal:  Exp Ther Med       Date:  2017-05-18       Impact factor: 2.447

4.  Antioxidant Activity and Neuroprotective Activity of Stilbenoids in Rat Primary Cortex Neurons via the PI3K/Akt Signalling Pathway.

Authors:  Haichao Wen; Zheng Fu; Yangji Wei; Xiaoxu Zhang; Liyan Ma; Liwei Gu; Jingming Li
Journal:  Molecules       Date:  2018-09-12       Impact factor: 4.411

5.  DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2).

Authors:  Chi-Wei Chen; Yongming Li; Shuya Hu; Wei Zhou; Yunxiao Meng; Zongzhu Li; Yi Zhang; Jing Sun; Zhou Bo; Melvin L DePamphilis; Yun Yen; Zhiyong Han; Wenge Zhu
Journal:  Oncogene       Date:  2018-12-05       Impact factor: 9.867

6.  The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells.

Authors:  Hyoun-Ji Kim; Kwang-Mo Yang; Yoo-Soo Park; Yoo-Jin Choi; Ji-Hyeon Yun; Cheol-Hun Son; Hong-Suk Suh; Min-Ho Jeong; Wol-Soon Jo
Journal:  Int J Oncol       Date:  2012-08-31       Impact factor: 5.650

7.  In vitro study on the antioxidant potentials of the leaves and fruits of Nauclea latifolia.

Authors:  Ademola O Ayeleso; Oluwafemi O Oguntibeju; Nicole L Brooks
Journal:  ScientificWorldJournal       Date:  2014-06-11

Review 8.  The Role of Resveratrol in Cancer Therapy.

Authors:  Jeong-Hyeon Ko; Gautam Sethi; Jae-Young Um; Muthu K Shanmugam; Frank Arfuso; Alan Prem Kumar; Anupam Bishayee; Kwang Seok Ahn
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

9.  New lipophilic piceatannol derivatives exhibiting antioxidant activity prepared by aromatic hydroxylation with 2-iodoxybenzoic acid (IBX).

Authors:  Roberta Bernini; Maurizio Barontini; Carmela Spatafora
Journal:  Molecules       Date:  2009-11-17       Impact factor: 4.411

Review 10.  Resveratrol: A Double-Edged Sword in Health Benefits.

Authors:  Bahare Salehi; Abhay Prakash Mishra; Manisha Nigam; Bilge Sener; Mehtap Kilic; Mehdi Sharifi-Rad; Patrick Valere Tsouh Fokou; Natália Martins; Javad Sharifi-Rad
Journal:  Biomedicines       Date:  2018-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.